BSEBoard Meeting1d ago · 21 Jul 2026, 11:59 am

Glaxosmithkline Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/08/2026 ,inter alia, to consider and approve approve and ....

GlaxoSmithKline Pharmaceuticals Ltd · 500660

✦ AI SummaryResults

GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 03/08/2026 to consider and approve the un-audited financial results for the first quarter ended 30th June 2026.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact5/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

GlaxoSmithKline Pharmaceuticals Ltd - 500660 - Board Meeting Intimation for Approve And Take On Record The Un-Audited Financial Results For The First Quarter Ended 30Th June 2026.

Attachments (1)

📄

c0184628-9e42-46cd-8b2d-7a6a6dca65be.pdf

pdf

Download →
View document text
GlaxoSmithKline Pharmaceuticals Limited. GSK House, Dr. Annie Besant Road, Worli, Mumbai - 400 030 Tel No: +91 22 2495 9595 Fax No: +91 22 2495 9494 Web: www.gsk-india.com Email: askus@gsk.com 21st July 2026 BSE LIMITED THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Phiroze Jeejeebhoy Towers Exchange Plaza, 5th Floor, Plot No. C/1, G Block Dalal Street Bandra-Kurla Complex, Bandra (East) Mumbai - 400001 Mumbai - 400051 Dear Sir, Board Meeting Pursuant to Regulations 29 & 33 of the Listing Obligations and Disclosure Requirements Regulations, 2015 (LODR), this is to inform you that a meeting of the Board of Directors of our Company will be held on Monday, 3rd August 2026, inter-alia, to consider, approve and take on record the Un-audited financial results for the first quarter ended 30th June 2026. Kindly take the same on records. Thanking you Yours faithfully For GlaxoSmithKline Pharmaceuticals Limited Ajay Nadkarni Vice President – Administration, Real Estate & Company Secretary CIN: L24239MH1924PLC001151